Clostridium difficile (C. difficile) pseudomembraneous colitis was diagnosed in a 13-year-old boy with Hodgkin's disease 3 months after autologous bone marrow transplantation. Hematopoiesis was fully reconstituted at the time. C. difficile infection occurred after gall bladder empyema had been treated conservatively with i.v. antibiotics and prophylactic 4-week administration of oral amoxicillin. C. difficile colitis was diagnosed early and intensive supportive therapy combined with administration of i.v. and subsequently oral vancomycin therapy failed. It is a phenomenon rarely seen and successful eradication of the clostridium infection was only achieved by a combination of higher dose vancomycin with metronidazole. During the post-colitis recovery the patient experienced a relapse of Hodgkin's disease and died following further surgical intervention 137 days post-transplantation.
An increasing number of patients with high risk or recurrent Hodgkin's disease have been receiving very intensive therapy followed by BMT. One of the serious post-transplant complications is infection. Clostridium difficile (C. difficile) pseudomembraneous enterocolitis (PMC) is a serious infectious complication exhibiting a variety of clinical presentations ranging from slight diarrhea to a very serious shocklike syndrome. 1, 2 Its etiology is linked to administration of a variety of broad-spectrum antibiotics, including the penicillins and cephalosporins. [3] [4] [5] [6] It most frequently affects patients in intensive care units and surgical and oncology wards. 7, 8 The initial source of the pathogen may be either endogenous or external and outbreaks can assume geographically localized endemic characteristics. The pathophysiology of the disease is related to both the enterotoxinlike toxin A and toxin B with its necrotic and cytotoxic effects. In neutropenic patients local invasion of the intestinal mucosa by C. difficile has also been observed. 9 Successful therapy depends on early clinical and microbiological diagnosis confirmed by colonoscopy. Laboratory examinations include microscopy, anaerobic stool culture and toxin A detection by immunoassay; sometimes latexagglutination is used. It is necessary to establish the toxicity of the respective clostridium strain. The enzymatic immunoassay is highly specific, sensitive and can be completed in 2 h. 10 The spectrum of available diagnostic tests for PMC has recently been augmented by the addition of molecular biology techniques, particularly PCR.
Case report
JH, a 13-year-old boy who had been diagnosed with Hodgkin's disease (HD) -lymphocyte depletion, clinical stage IV with multifocal skeletal metastases -was admitted to our institute in March 1994. Initial high-dose induction therapy resulted in only partial remission (PR), and he was entered into the mega-therapy regimen followed by bone marrow (BM) rescue using autologous BM. BM transplantation was carried out while the patient was in PR in March 1995 and no complications developed in the posttransplantation period. White cell reconstitution (day +13 for ANC у 0.5 × 10 9 /l for 3 consecutive days) was followed by full hematopoietic reconstitution and the patient was discharged on day +18. Soon after his discharge, he complained of abdominal pain and dyspepsia and was readmitted on day +24. On admission, tenderness on palpation was noted in the right hypogastrium with no peritoneal signs. He was afebrile but subsequently developed a fever of 38°C and began vomiting green-yellow colored watery liquid. Laboratory investigations showed an increased sedimentation rate (63/h), 3.9 × 10 9 /l WBC, 1.6 × 10 9 /l ANC. All other biochemical tests were within normal limits and bacteriological examinations proved negative. On ultrasound a fluid-filled gall bladder was interpreted as empyema and a course of timentin (ticarcillin + clavulanate) i.v. 3.2 g four times a day was started. Because there was no change in clinical or sonographic status after 4 days, antibiotics were changed to cefobid (cefoperazone) i.v. 1.0 g four times a day. Cefobid is excreted by the hepato-biliary system and is known to enter even the obstructed gall bladder. Following the change in medication, clinical status and sonographic results improved over the next few days. With no further evidence of infection, the patient was discharged after 14 days and, because of his known intolerance of co-trimoxazole, was started on prophylactic oral amoxicillin 500 mg four times a day for a period of 4 weeks. He was complication-free until day +92, when he complained of abdominal cramping. On examination no abdominal tenderness was found. His temperature, sedimentation rate and WBC were normal. Over the next few days, however, he developed watery diarrhea, frequent abdominal cramps and his abdomen became tender on palpitation. No peritoneal irritation was noted. Rectal swab and stool collection for culture was performed and the patient was prescribed diet, diphenoxylate + atropin (reasec) and KCl.
His clinical status deteriorated further with frequent hemorrhagic diarrhea. Because of the clinical status and negative anaerobic stool cultures, PMC was considered in the differential diagnosis. A stool sample was positive for the presence of C. difficile toxin by an enzymatic immunoassay (diagnostic kit TOXIN CD, Becton Dickinson, MD, USA). Vancomycin i.v. 40 mg/kg daily and oral 125 mg four times a day was started immediately. Colonoscopy showed angiodysplastic changes, ulcerations exhibiting raised margins with whitish centers and luminal hemorrhage. However, the patient's clinical status and abdominal pains continued to worsen. Diminished peristalsis was accompanied by the appearance of a palpable mass in the left hypogastrium. Vancomycin was administered by a nasogastric tube because the patient could not swallow. Colonoscopy showed progressive disease resulting in ulcerative stenotic closure of the intestinal lumen 40 cm proximal to the rectum. Repeated stool assays showed continuous presence of the C. difficile toxin. On day 8 of the therapeutic regimen, i.v. vancomycin was discontinued and oral vancomycin increased to 400 mg four times a day. Metronidazole oral 500 mg three times a day was added. This combination proved effective and was administered for a total of 19 days. Clinical status gradually improved and subsequent assays for clostridium toxin were negative. The diarrhea subsided and the patient was started on nasogastric realimentation with survimed followed by gradual introduction of regular diet. Because of the persisting stenosis of the descending colon he was started on i.v. urbason (methylprednisolone) 1 mg/kg which was continued for 23 days when oral prednisolone was substituted. After a temporary improvement, the patient again began complaining of abdominal cramping. There was no diarrhea and an assay for clostridium toxin was negative. Colonoscopy showed progression of post-inflammatory changes with pronounced fixed stenoses in the descending colon. A transverse colostomy was carried out. During an unremarkable postoperative period, however, a relapse of Hodgkin's disease occurred which progressed rapidly, and the patient died on day +137 post-transplant.
Discussion
Wingard 11 has classified infectious complications occurring post-transplantation according to the causative pathogens. Generally, the most frequent are gram-positive, mycotic and viral (VZV, HSV, EBV, CMV) infections. Anaerobic infections occur infrequently in both the early and later stages. In spite of this, it is necessary to consider neutropenic patients given long-term broad-spectrum antibiotics to be at risk for C. difficile infection. 7, [12] [13] [14] The source of infection can either be endogenous or exogenous. It is difficult to ascertain the source of infection in our patient. The most plausible explanation seems to be that the 4-week prophylactic administration of amoxicillin rendered him susceptible. The infection manifested itself 3 weeks after the cessation of antibiotic therapy, which corresponds to the 2-4 weeks interval associated with PMC. In addition, our patient was 3 months post-transplant and still significantly immunodeficient. In retrospect, it is also possible that the early stages of relapsing HD contributed to his susceptibility to C. difficile infection.
An early diagnosis of PMC is known to significantly impact upon the outcome. 15 In our case an early diagnosis by immunoassay and colonoscopy was made. The fundamental therapeutic approach to PMC is an immediate discontinuation of broad-spectrum antibiotics and administration of specific therapy. 16, 17 Vancomycin and metronidazole are considered to be the first choices. 2, 5, 7, [12] [13] [14] 18, 19 Because of the low concentration of these drugs in intestinal lumen when administered parenterally, they must be given orally. Administration by a nasogastric tube is sometimes necessary. 20 Clinical improvement should be expected within 2 days after vancomycin and 3 days after metronidazole. [21] [22] [23] [24] [25] [26] In our case, no clinical improvement was observed after administration of vancomycin alone. The patient's condition and the results of laboratory and colonoscopic examinations deteriorated further in spite of administration of the recommended oral vancomycin dosage of 125 mg four times a day, which should result in an approximate 300-1000 mg/l stool concentration. 9 To our knowledge, no such resistance to vancomycin has been previously documented in the literature. Robert et al 27 have described the in vivo resistance of C. difficile to tetracycline, clindamycin, and in vitro resistance of C. difficile to vancomycin. Perhaps the failure of vancomycin in our patient was due to diminished intestinal peristalsis and thus to a decreased local availability of the drug. This would also explain the fact that an increased dosage of vancomycin in combination with metronidazole has proven effective. Metronidazole pharmacokinetics differ from those of vancomycin in that conditions resulting in a near ileus do not seem to interfere with drug penetration of the intestinal wall. Furthermore, the two-drug combination results in a synergistic effect because of their different modes of action. Metronidazole has been described previously as the preferred drug because of its lower cost and because of the possible presence of oral vancomycin-resistant enterococci. 22 C. difficile infection can respond to aggressive oral antibiotic treatment and should be considered in post-BMT patients who have diarrhea.
